The DOI matches its Crossref record; 191 of the 193 references it cites were found in a registry or an index.
Diabetic Kidney Disease: A Report From an ADA Consensus Conference
Open accessAbstract
The incidence and prevalence of diabetes mellitus have grown significantly throughout the world, due primarily to the increase in type 2 diabetes. This overall increase in the number of people with diabetes has had a major impact on development of diabetic kidney disease (DKD), one of the most frequent complications of both types of diabetes. DKD is the leading cause of end-stage renal disease (ESRD), accounting for approximately 50% of cases in the developed world. Although incidence rates for ESRD attributable to DKD have recently stabilized, these rates continue to rise in high-risk groups such as middle-aged African Americans, Native Americans, and Hispanics. The costs of care for people with DKD are extraordinarily high. In the Medicare population alone, DKD-related expenditures among this mostly older group were nearly $25 billion in 2011. Due to the high human and societal costs, the Consensus Conference on Chronic Kidney Disease and Diabetes was convened by the American Diabetes Association in collaboration with the American Society of Nephrology and the National Kidney Foundation to appraise issues regarding patient management, highlighting current practices and new directions. Major topic areas in DKD included 1) identification and monitoring, 2) cardiovascular disease and management of dyslipidemia, 3) hypertension and use of renin-angiotensin-aldosterone system blockade and mineralocorticoid receptor blockade, 4) glycemia measurement, hypoglycemia, and drug therapies, 5) nutrition and general care in advanced-stage chronic kidney disease, 6) children and adolescents, and 7) multidisciplinary approaches and medical home models for health care delivery. This current state summary and research recommendations are designed to guide advances in care and the generation of new knowledge that will meaningfully improve life for people with DKD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“A1C levels are also less reliable at advanced CKD stages (64,65).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [64]
The cited source says what the claim attributes to it.
In the citing paper
“A1C levels are also less reliable at advanced CKD stages (63,64).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [63]
In the citing paper
“There is no evidence that adjusting the daily level of protein intake (typically 1-1.5 g/kg body wt/day or 15-20% total calories) will improve health, and research is inconclusive regarding the ideal amount of dietary protein to optimize either glycemic management or CVD risk (159,195).”
From 5. Facilitating Positive Health Behaviors and Well-being to Improve Health Outcomes:Standards of Care in Diabetes—2023 (2023) · cites this paper as [195]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED: Primary Prevention of Cardiovascular Disease with a Mediterranean Diet
Estruch, R., Ros, E., Salas-Salvadó, J., Covas, M.-I., Corella, D., Arós, F., Gómez-Gracia, E., Ruiz-Gutiérrez, V., Fiol, M., Lapetra, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1200303 · Cited by 4,257
RetractedAhmed, A., Jorna, T., & Bhandari, S. (2016) · The Nephron journals/Nephron journals · doi:10.1159/000447068 · Cited by 11,782
Standards of Medical Care in Diabetes
Power, D. V. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1593 · Cited by 8,676
James, P. A., Oparil, S., Carter, B. L., Cushman, W. C., Dennison-Himmelfarb, C., Handler, J., Lackland, D. T., LeFevre, M. L., MacKenzie, T. D., Ogedegbe, O., et al. (2014) · JAMA · doi:10.1001/jama.2013.284427 · Cited by 7,950
Self-citationBrenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Adherence to Long-Term Therapies: Evidence for Action
Geest, S. D., & Sabate, E. J. (2003) · European Journal of Cardiovascular Nursing · doi:10.1016/s1474-5151(03)00091-4 · Cited by 6,310
Lewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311113292004 · Cited by 5,394
Standards of medical care in diabetes—2014
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s014 · Cited by 4,572
Flagged first, then by citations
2 of the 193 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 101–200 of 1,000
Pleiotropic effects of type 2 diabetes management strategies on renal risk factors
Muskiet, M. H. A., Tonneijck, L., Smits, M. M., Kramer, M. H. H., Heerspink, H. J. L., & van Raalte, D. H. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00030-3 · Cited by 83
Robust clinical marker identification for diabetic kidney disease with ensemble feature selection
Song, X., Waitman, L. R., Hu, Y. Q., Yu, A. S. L., Robins, D., & Liu, M. (2018) · Journal of the American Medical Informatics Association · doi:10.1093/jamia/ocy165 · Cited by 82
Paramasivam, P., Rome, S., Chandrakumar, S., Gastebois, C., Meugnier, E., Mohan, V., & Balasubramanyam, M. (2018) · Diabetes & Metabolism · doi:10.1016/j.diabet.2018.08.004 · Cited by 81
on behalf of the ADVANCE Collaborative Group, Oshima, M., Jun, M., Ohkuma, T., Toyama, T., Wada, T., Cooper, M. E., Hadjadj, S., Hamet, P., Harrap, S. B., et al. (2019) · Diabetologia · doi:10.1007/s00125-019-4948-4 · Cited by 82
Parker, V. E. R., Hoang, T., Schlichthaar, H., Gibb, F. W., Wenzel, B., Posch, M. G., Rose, L., Chang, Y., Petrone, M., Hansen, L., et al. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14712 · Cited by 80
Allen, A. O., Iqbal, Z., Green‐Saxena, A., Hurtado, M., Hoffman, J. L., Mao, Q., & Das, R. (2022) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002560 · Cited by 80
Ling, J., Ng, J. K., Chan, J. C. N., & Chow, E. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.869899 · Cited by 82
Claessen, H., Narres, M., Haastert, B., Arend, W., Hoffmann, F., Morbach, S., Rümenapf, G., Kvitkina, T., Friedel, H., Günster, C., et al. (2018) · Clinical Epidemiology · doi:10.2147/clep.s146484 · Cited by 81
Yubero‐Serrano, E. M., Woodward, M., Poretsky, L., Vlassara, H., & Striker, G. E. (2015) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.07750814 · Cited by 79
Song, X., Waitman, L. R., Yu, A. S., Robbins, D. C., Hu, Y., & Liu, M. (2020) · JMIR Medical Informatics · doi:10.2196/15510 · Cited by 77
Davies, M. J., Chatterjee, S., & Khunti, K. (2016) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s82008 · Cited by 78
Li, Z., Alzogool, M., Xiao, J., Zhang, S., Zeng, P. C., & Lan, Y. (2018) · Acta Diabetologica · doi:10.1007/s00592-018-1202-3 · Cited by 77
Elendu, C., Okah, M. J., Fiemotongha, K. J. D., Boluwatife, A. I., Bassey, B. N., Omeludike, E., & Obidigbo, B. T. (2023) · Medicine · doi:10.1097/md.0000000000035397 · Cited by 77
Pharmacological potential of Astragali Radix for the treatment of kidney diseases
Shi, Y., Shi, X., Zhao, M., Ma, S., & Zhang, Y. (2023) · Phytomedicine · doi:10.1016/j.phymed.2023.155196 · Cited by 74
Therapeutic Considerations for Antihyperglycemic Agents in Diabetic Kidney Disease
Neumiller, J. J., Alicic, R. Z., & Tuttle, K. R. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016121372 · Cited by 72
Self-citationLu, X., & Zhao, C. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-1792-1_7 · Cited by 77
Betônico, C. D. C. R., Titan, S., Corrêa‐Giannella, M. L., Nery, M., & Queiroz, M. S. (2016) · Clinics · doi:10.6061/clinics/2016(01)08 · Cited by 75
Tong, X., Yu, Q., Ankawi, G., Pang, B., Yang, B., & Yang, H. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00888-w · Cited by 73
Current Challenges in Diabetic Nephropathy: Early Diagnosis and Ways to Improve Outcomes
Kim, S. S., Kim, J. H., & Kim, I. J. (2016) · Endocrinology and Metabolism · doi:10.3803/enm.2016.31.2.245 · Cited by 73
Mitochondrial Pathophysiology on Chronic Kidney Disease
Braga, P. C., Alves, M. G., Rodrigues, A. S., & Oliveira, P. F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031776 · Cited by 72
Anagliptin in the treatment of type 2 diabetes: safety, efficacy, and patient acceptability
Ito, H., Nishio, S., & Abe, M. (2015) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s54679 · Cited by 70
Wu, W., Hu, W., Han, W.-B., Liu, Y., Tu, Y., Yang, H., Fang, Q., Zhou, M.-Y., Wan, Z.-Y., Tang, R., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00443 · Cited by 69
Standl, E., Schnell, O., McGuire, D. K., Ceriello, A., & Rydén, L. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30033-5 · Cited by 68
Ghai, V., Wu, X., Bheda-Malge, A., Argyropoulos, C., Bernardo, J. F., Orchard, T. J., Galas, D. J., & Wang, K. (2017) · Kidney International Reports · doi:10.1016/j.ekir.2017.11.019 · Cited by 68
Bramlage, P., Lanzinger, S., van Mark, G., Hess, E., Fahrner, S., Heyer, C. H. J., Friebe, M., Seufert, J., Danne, T., & Holl, R. W. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0837-x · Cited by 65
AMPK signalling: Implications for podocyte biology in diabetic nephropathy
Szrejder, M., & Piwkowska, A. (2019) · Biology of the Cell · doi:10.1111/boc.201800077 · Cited by 65
Yu, D., Wang, Z., Zhang, X., Qu, B., Cai, Y., Ma, S., Zhao, Z., & Simmons, D. S. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab533 · Cited by 64
Long-term Outcomes in Youths with Diabetes Mellitus
White, N. H. (2015) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2015.04.004 · Cited by 64
Bashier, A. M., Hussain, A. K. B., Abdelgadir, E., Alawadi, F., Sabbour, H. M., & CHILTON, R. J. (2019) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-019-0476-0 · Cited by 63
Inhibition of Ceramide Accumulation in Podocytes by Myriocin Prevents Diabetic Nephropathy
Woo, C.-Y., Baek, J. Y., Kim, A., Hong, C. H., Yoon, J. E., Kim, H. S., Yoo, H. J., Park, T., Kc, R., Lee, K., et al. (2019) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2019.0063 · Cited by 62
Harris, S. T., Patorno, E., Zhuo, M., Kim, S. C., & Paik, J. M. (2021) · Diabetes Care · doi:10.2337/dc21-0529 · Cited by 63
Wada, T., Hosoya, T., Honda, D., Sakamoto, R., Narita, K., Sasaki, T., Okui, D., & Kimura, K. (2018) · Clinical and Experimental Nephrology · doi:10.1007/s10157-018-1530-1 · Cited by 61
Wang, Y., Yang, S., Zhou, Q., Zhang, H., & Yi, B. (2019) · Kidney and Blood Pressure Research · doi:10.1159/000498838 · Cited by 60
Liu, J., Pek, S. L. T., Ang, K., Subramaniam, T., Lim, S. C., & study, F. S. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-00930 · Cited by 60
Wu, L., Li, X.-Q., Chang, D., Zhang, H., Li, J., Wu, S., Zhang, L., Chen, M., & Zhao, M. (2018) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfy314 · Cited by 60
Sloan, L. A. (2019) · Journal of Diabetes · doi:10.1111/1753-0407.12969 · Cited by 62
Yang, Q., Lang, Y., Yang, W., Yang, F., Yang, J., Wu, Y., Xiao, X., Qin, C., Zou, Y., Zhao, Y., et al. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110592 · Cited by 62
Changes in Albuminuria and the Risk of Major Clinical Outcomes in Diabetes: Results From ADVANCE-ON
Jun, M., Ohkuma, T., Zoungas, S., Colagiuri, S., Mancia, G., Marre, M., Matthews, D. R., Poulter, N. R., Williams, B., Rodgers, A., et al. (2017) · Diabetes Care · doi:10.2337/dc17-1467 · Cited by 59
Prognosis and treatment of diabetic nephropathy: Recent advances and perspectives
Rossing, P. R., Persson, F., & Frimodt‐Møller, M. (2018) · Néphrologie & Thérapeutique · doi:10.1016/j.nephro.2018.02.007 · Cited by 62
Artificial Intelligence for Predicting and Diagnosing Complications of Diabetes
Huang, J. K., Yeung, A. M., Armstrong, D. G., Battarbee, A. N., Cuadros, J. A., Espinoza, J., Kleinberg, S., Mathioudakis, N. N., Swerdlow, M. A., & Klonoff, D. C. (2022) · Journal of Diabetes Science and Technology · doi:10.1177/19322968221124583 · Cited by 61
Diabetes mellitus type 2 in adults
Dedov, I. I., Shestakova, M. V., Mayorov, A. Y., Шамхалова, М. Ш., Sukhareva, O. Y., Galstyan, G. R., Tokmakova, A. Y., Nikonova, T. V., Surkova, E. V., Кононенко, И. В., et al. (2020) · Diabetes Mellitus · doi:10.14341/dm12507 · Cited by 60
Dutta, D., Chittawar, S., Qureshi, Z., Surana, V., Khandare, S., & Dubey, T. (2017) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_197_17 · Cited by 57
The utility of magnetic resonance imaging for noninvasive evaluation of diabetic nephropathy
Brown, R. S., Sun, M. R. M., Stillman, I. E., Russell, T. L., Rosas, S. E., & Wei, J. L. (2019) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfz066 · Cited by 57
Kim, S. R., Lee, Y., Lee, S., Kang, E. S., Soo, B., Kim, J., & Lee, B. (2016) · Medicine · doi:10.1097/md.0000000000004114 · Cited by 55
Suppressor of Cytokine Signaling-1 Peptidomimetic Limits Progression of Diabetic Nephropathy
Recio, C., Lázaro, I., Oguiza, A., Lopez‐Sanz, L., Bernal, S., Blanco, J., Egido, J., & Gómez‐Guerrero, C. (2016) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016020237 · Cited by 56
Progression of diabetic kidney disease in T2DN rats
Palygin, O., Spires, D. R., Levchenko, V., Bohovyk, R., Fedoriuk, M., Klemens, C. A., Sykes, O., Bukowy, J. D., Cowley, A. W., Lazar, J., et al. (2019) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00246.2019 · Cited by 55
Perloff, J. N., Clarke, S. P., DesRoches, C. M., O’Reilly-Jacob, M., & Buerhaus, P. I. (2017) · Medical Care Research and Review · doi:10.1177/1077558717732402 · Cited by 54
Galindo, R. J., Ali, M. K., Funni, S. A., Dodge, A. B., Kurani, S. S., Shah, N. D., Umpierrez, G. E., & McCoy, R. G. (2022) · Diabetes Care · doi:10.2337/dc21-1579 · Cited by 53
Folkerts, K., Petruski‐Ivleva, N., Kelly, A., Fried, L. F., Blankenburg, M., Gay, A., & Kovesdy, C. P. (2020) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2020.26.12.1506 · Cited by 52
Shubrook, J. H., Neumiller, J. J., & Wright, E. E. (2021) · Postgraduate Medicine · doi:10.1080/00325481.2021.2009726 · Cited by 54
Self-citationFolkerts, K., Petruski‐Ivleva, N., Comerford, E., Blankenburg, M., Evers, T., Gay, A., Fried, L. F., & Kovesdy, C. P. (2021) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2020.07.037 · Cited by 52
Liu, W., Gao, Y., Zhou, Y., Yu, F., Li, X., & Zhang, N. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.881835 · Cited by 52
Liu, J., Lim, S. C., Yeoh, L. Y., Su, C., Tai, B., Low, S. K., Fun, S., Tavintharan, S., Chia, K. S., Tai, E. S., et al. (2015) · Diabetic Medicine · doi:10.1111/dme.13020 · Cited by 52
An, X., Zhang, L., Yuan, Y., Wang, B., Yao, Q., Li, L., Zhang, J., He, M., & Zhang, J. (2017) · Scientific Reports · doi:10.1038/s41598-017-06844-2 · Cited by 52
Li, Z., Wen, X., Zeng, P. C., Liao, Y., Fan, S.-X., Zhang, Y., Li, Y., Xiao, J., & Lan, Y. (2019) · Acta Diabetologica · doi:10.1007/s00592-019-01288-8 · Cited by 52
Stephens, J. W., Brown, K. E., & Min, T. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13942 · Cited by 54
Review of potential biomarkers of inflammation and kidney injury in diabetic kidney disease
Khanijou, V., Zafari, N., Coughlan, M. T., MacIsaac, R. J., & Ekinci, E. I. (2022) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3556 · Cited by 52
Management of diabetic ketoacidosis
Barski, L., Golbets, E., Jotkowitz, A., & Schwarzfuchs, D. (2023) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2023.07.005 · Cited by 51
Li, J., Guo, K., Qiu, J., Xue, S., Pi, L., Li, X., Huang, G., Xie, Z., & Zhou, Z. (2025) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003428 · Cited by 51
Clinical and pathological factors associated with progression of diabetic nephropathy
Liang, S., Cai, G., & Chen, X. (2017) · Nephrology · doi:10.1111/nep.13182 · Cited by 52
Glycated albumin as biomarker: Evidence and its outcomes
Kohzuma, T., Tao, X., & Koga, M. (2021) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2021.108040 · Cited by 51
Zhang, X., Zhang, J., Ren, Y., Sun, R., & Zhai, X. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1368481 · Cited by 53
hs-CRP Is Associated With Incident Diabetic Nephropathy: Findings From the Jackson Heart Study
Sinha, S. K., Nicholas, S. B., Sung, J. H., Correa, A., Rajavashisth, T. B., Norris, K. C., & Lee, J. E. (2019) · Diabetes Care · doi:10.2337/dc18-2563 · Cited by 51
Risk of hypoglycemia following hospital discharge in patients with diabetes and acute kidney injury
Hung, A. M., Siew, E. D., Wilson, O. D., Perkins, A. M., Greevy, R. A., Horner, J., Abdel-Kader, K., Parr, S. K., Roumie, C. L., Griffin, M. R., et al. (2018) · Diabetes Care · doi:10.2337/dc17-1237 · Cited by 49
Comorbidity of patients with noncommunicable diseases in general practice. Eurasian guidelines
Drapkina, O. M., Васильевна, К. А., Калинина, А. М., Avdeev, S. N., Викторович, А. М., Алексеева, Л. И., Almazova, I. I., Andreenko, Е. Y., Antipushina, D. N., Balanova, Y. А., et al. (2024) · CARDIOVASCULAR THERAPY AND PREVENTION · doi:10.15829/1728-8800-2024-3996 · Cited by 55
Transforming growth factor β (TGFβ) and related molecules in chronic kidney disease (CKD)
Huynh, P., & Chai, Z. (2019) · Clinical Science · doi:10.1042/cs20180438 · Cited by 50
Managing Diabetes and Cardiovascular Risk in Chronic Kidney Disease Patients
Lovre, D., Shah, S., Sihota, A., & Fonseca, V. A. (2017) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2017.10.006 · Cited by 49
Yao, L., Li, J., Li, L., Li, X., Zhang, R., Zhang, Y., & Xinmin, M. (2019) · BMC Complementary and Alternative Medicine · doi:10.1186/s12906-018-2410-7 · Cited by 48
Lin, Y., Wang, T.-H., Tsai, M., Wu, V. C., Tseng, C.-J., Lin, M., Li, Y., Chang, C., Chou, T., Tsai, T., et al. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01793-9 · Cited by 55
Salti, T., Khazim, K., Haddad, R., Campisi‐Pinto, S., Bar‐Sela, G., & Cohen, I. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01270 · Cited by 47
Management of diabetic renal disease.
Eboh, C., & Chowdhury, T. A. (2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2305-5839.2015.06.25 · Cited by 47
Fernández‐Fernández, B., Fernández-Prado, R., Górriz, J. L., Martínez‐Castelao, A., Navarro‐González, J. F., Porrini, E., Soler, M. J., & Ortíz, A. (2019) · Clinical Kidney Journal · doi:10.1093/ckj/sfz070 · Cited by 48
Metabolic reprogramming: A novel therapeutic target in diabetic kidney disease
Wang, M., Pang, Y., Guo, Y., Tian, L., Liu, Y., Shen, C., Liu, M., Meng, Y., Cai, Z., Wang, Y., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.970601 · Cited by 47
Nichols, G. A., Déruaz‐Luyet, A., Hauske, S. J., & Brodovicz, K. G. (2017) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2017.12.003 · Cited by 46
Wang, C., Zhang, W., Wang, Y., Wan, H., Chen, Y., Xia, F., Zhang, K., Wang, N., & Lu, Y. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0901-6 · Cited by 47
Urinary biomarkers in diabetic nephropathy
Fard, E. S., Taghvimi, S., Karimi, F., Vahedi, F., Khatami, S. H., Behrooj, H., Hayati, M. D., Movahedpour, A., & Ghasemi, H. (2024) · Clinica Chimica Acta · doi:10.1016/j.cca.2024.119762 · Cited by 45
Hamdy, O., & Yusof, B. N. M. (2016) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2016.06.010 · Cited by 49
Ahn, H., Kim, J. H., Jeong, H., Yu, J., Yeom, J., Song, S. H., Kim, S. S., Kim, I. J., & Kim, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124236 · Cited by 46
High FIB4 index is an independent risk factor of diabetic kidney disease in type 2 diabetes
Saito, H., Tanabe, H., Kudo, A., Machii, N., Higa, M., Yamaguchi, S., Maimaituxun, G., Abe, K., Takahashi, A., Tanaka, K., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-88285-6 · Cited by 44
Vascular growth factors play critical roles in kidney glomeruli
Gnudi, L., Benedetti, S., Woolf, A. S., & Long, D. A. (2015) · Clinical Science · doi:10.1042/cs20150403 · Cited by 44
Lo, C., Jun, M., Badve, S. V., Pilmore, H., White, S. L., Hawley, C. M., Cass, A., Perkovic, V., & Zoungas, S. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009966.pub2 · Cited by 44
Chu, Y.-W., Lin, H.-M., Wang, J.-J., Weng, S., Lin, C., & Chien, C.-C. (2017) · PLoS ONE · doi:10.1371/journal.pone.0174601 · Cited by 45
Khan, A. H., Kolb, L. L., Skibba, M. E., Hartmann, M., Blöcher, R., Proschak, E., & Imig, J. D. (2018) · Diabetologia · doi:10.1007/s00125-018-4685-0 · Cited by 44
Carnosine and Diabetic Nephropathy
Peters, V., Yard, B. A., & Schmitt, C. P. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666190326111851 · Cited by 44
Renal Protective Effect of DPP-4 Inhibitors in Type 2 Diabetes Mellitus Patients: A Cohort Study
Kim, Y., Byun, J., Yoon, D., Jeon, J. Y., Han, S. J., Kim, D. J., Lee, K. W., Park, R. W., & Kim, H. J. (2016) · Journal of Diabetes Research · doi:10.1155/2016/1423191 · Cited by 44
Zhu, Z., Luan, G., Peng, S., Fang, Y., Fang, Q., Shen, S., Wu, K., Qian, S., Jia, W., Ye, J., et al. (2023) · Phytomedicine · doi:10.1016/j.phymed.2023.154975 · Cited by 43
Podocyte Death in Diabetic Kidney Disease: Potential Molecular Mechanisms and Therapeutic Targets
Zhong, S., Wang, N., & Zhang, C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25169035 · Cited by 44
Glycemic Control as Primary Prevention for Diabetic Kidney Disease
MacIsaac, R. J., Jerums, G., & Ekinci, E. I. (2018) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2017.11.003 · Cited by 43
Yun, K.-J., Kim, H. J., Kim, M. K., Kwon, H., Baek, K., Roh, Y., & Song, K. (2016) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2016.40.6.473 · Cited by 42
Zhou, Z., Chaudhari, P., Yang, H., Fang, A., Zhao, J., Law, E. H., Wu, E. Q., Jiang, R., & Seifeldin, R. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0256-5 · Cited by 42
Combination of Changes in Estimated GFR and Albuminuria and the Risk of Major Clinical Outcomes
Ohkuma, T., Jun, M., Chalmers, J. P., Cooper, M. E., Hamet, P., Harrap, S. B., Zoungas, S., Perkovic, V., Woodward, M., & on behalf of the ADVANCE Collaborative Group (2019) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.13391118 · Cited by 42
Huang, Y., Xu, J., Wu, X., Chen, X., Bai, X., Zhuang, Y., Fang, J., & Lin, X. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00459 · Cited by 42
Chen, Q., Ren, D., Wu, J., Yu, H., Chen, X., Wang, J., Zhang, Y., Liu, M., & Wang, T. (2020) · Journal of Natural Medicines · doi:10.1007/s11418-020-01452-3 · Cited by 43
Xu, Y., Surapaneni, A., Alkas, J., Evans, M., Shin, J., Selvin, E., Chang, A. R., Grams, M. E., & Carrero, J. J. (2020) · Diabetes Care · doi:10.2337/dc20-1588 · Cited by 42
Hirano, T., Satoh, N., Kodera, R., Hirashima, T., Suzuki, N., Aoki, E., Oshima, T., Hosoya, M., Fujita, M., Hayashi, T., et al. (2021) · Journal of Diabetes Investigation · doi:10.1111/jdi.13697 · Cited by 42
Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
Kawanami, D., Takashi, Y., Muta, Y., Oda, N., Nagata, D., Takahashi, H., & Tanabe, M. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.754239 · Cited by 43
Mechanisms of metabolic memory and renal hypoxia as a therapeutic target in diabetic kidney disease
Hirakawa, Y., Tanaka, T., & Nangaku, M. (2017) · Journal of Diabetes Investigation · doi:10.1111/jdi.12624 · Cited by 43
Chu, L., Bhogal, S. K., Lin, P., Steele, A., Fuller, M. T., Ciaccia, A., & Abitbol, A. (2022) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2022.01.008 · Cited by 41
Serum uromodulin is associated with impaired glucose metabolism
Leiherer, A., Muendlein, A., Saely, C. H., Kinz, E., Brandtner, E. M., Fraunberger, P., & Drexel, H. (2017) · Medicine · doi:10.1097/md.0000000000005798 · Cited by 41
Emirates Diabetes Society Consensus Guidelines for the Management of Type 2 Diabetes Mellitus – 2020
Alawadi, F., Abusnana, S., Afandi, B. O., Aldahmani, K. M., Hajeri, O. M. A., Aljaberi, K., Alkaabi, J., Al-Madani, A., Bashier, A. M., Beshyah, S., et al. (2020) · Dubai Diabetes and Endocrinology Journal · doi:10.1159/000506508 · Cited by 43
Metadata
- Authors
- Tuttle, K. R., Bakris, G. L., Bilous, R. W., Chiang, J. L., de Boer, I. H., Goldstein-Fuchs, J., Hirsch, I. B., Kalantar-Zadeh, K., Narva, A. S., Navaneethan, S. D., Neumiller, J. J., Patel, U. D., Ratner, R. E., Whaley-Connell, A. T., & Molitch, M. E.
- Affiliations
- University of Washington (US)
- National Kidney Foundation (US)
- Newcastle University (GB)
- American Diabetes Association (US)
- Division of Nephrology, University of Washington, Seattle, WA
- Sierra Nevada Nephrology Consultants, Reno, NV
- School of Medicine, University of California, Irvine, Irvine, CA
- National Institutes of Health (US)
- Cleveland Clinic (US)
- Washington State University Spokane (US)
- Duke University (US)
- Harry S. Truman Memorial Veterans Hospital, Columbia, MO, and Department of Internal Medicine, Division of Nephrology and Hypertension, University of Missouri School of Medicine, Columbia, MO
- Northwestern University (US)
- Corresponding author
- Chiang, Jane L.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2014-09-10
- Volume
- 37
- Issue
- 10
- Pages
- 2864-2883
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC4170131
- OpenAlex
- W2072070798
- Semantic Scholar
- 0c6864a569d8918ea51eda33aae122cff819ac65
- Cited by
- 1,153
- References
- 193
- Citations by year
- 2026: 90 · 2025: 104 · 2024: 107 · 2023: 131 · 2022: 128 · 2021: 118 · 2020: 130 · 2019: 87 · 2018: 87 · 2017: 72 · 2016: 65 · 2015: 27 · 2014: 6
- FWCI
- 44.80
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- AstraZeneca
- Sanofi
- Gilead Sciences
- Halozyme
- Luitpold Pharmaceuticals
- Angion
- Novo Nordisk
- CSL Limited
- National Institutes of Health (UL1TR000430)
- Relypsa
- National Institute of Diabetes and Digestive and Kidney Diseases
- National Center for Advancing Translational Sciences
- Daiichi Sankyo Europe
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Nephrology › Dialysis and Renal Disease Management
- Keywords
- diabetic nephropathy, end-stage renal disease, type 2 diabetes, chronic kidney disease, cardiovascular disease, dyslipidemia, hypertension, renin-angiotensin-aldosterone system blockade, mineralocorticoid receptor antagonists, glycemic control, hypoglycemia, pharmacotherapy, pediatric diabetes, multidisciplinary care, patient-centered medical home, health care delivery
- MeSH terms
- Adolescent, Aged, Antihypertensive Agents, Blood Glucose, Cardiovascular Diseases, Child, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Humans, Kidney Function Tests, Middle Aged, Incidence, Prevalence, Renal Insufficiency, Chronic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
